"Designing Growth Strategies is in our DNA"

U.S. Hepatitis B Vaccine Market Size, Share & COVID-19 Impact Analysis, By Type (Single Antigen and Combination), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, and Others), and Country Forecast, 2023-2030

Last Updated: July 08, 2024 | Format: PDF | Report ID: FBI108637



Play Audio Listen to Audio Version

The U.S. hepatitis B vaccine market size was valued at USD 2.49 billion in 2022 and is projected to grow at a CAGR of 4.5% during the forecast period. 

The prevalence of hepatitis B infection is increasing among adults and children nationwide. The high prevalence is owing to a rise in the spread of the hepatitis B virus through blood, semen, or other body fluids among the population. Thus, the increase in the number of hepatitis B-infected population has led to the enforcement of new strategies by several public health agencies to eliminate the viral infection.

  • As per Hepatitis B Foundation data published in April 2022, the U.S. Centers for Disease Control and Prevention (CDC) announced the adoption of universal hepatitis B vaccination for all adults aged 19-59 in the U.S., recommended by its Advisory Committee on Immunization Practices (ACIP).

The rising incidence of hepatitis infection has increased demand for these vaccines nationwide, further propelling the market growth. The impact of the COVID-19 pandemic led to a decline in market growth in 2020. The decline was owing to limited hepatitis B immunizations across the country.


High Uptake of Hepatitis B Vaccination Among the U.S. Children

The U.S. government is highly emphasizing in public health interventions, such as routine hepatitis vaccination among adults and universal vaccination in hospitals among infants across the nation. Such initiatives increase the uptake of vaccines among the population and support the elimination of the rising incidence of hepatitis B infection, further boosting the market growth.

According to the Organization for Economic Co-operation and Development (OECD) statistics in 2021, the hepatitis B (HepB3) immunization coverage among 1-year-olds was around 92.0% across the U.S.

Thus, rising government initiatives and increasing vaccination uptake among the U.S. population aids market growth.


Rising Launch of Advanced Vaccines to Augment Market Growth

The demand for vaccines is increasing in the U.S., to prevent hepatitis B infection among adults and infants. Thus, the industry players are now focusing on strategic initiatives for introducing advanced vaccines across the U.S. Such initiatives increase the presence and adoption of hepatitis B vaccines in the country, further propelling U.S. hepatitis b vaccine market growth.

  • In March 2022, VBI Vaccines Inc. announced the launch of PreHevbrio, a 3-antigen hepatitis B vaccine in the U.S. to prevent hepatitis B in Adults.

Thus, rising initiatives of market players to develop a vaccine with an advanced mechanism of action are expected to augment market growth.

Request a Free sample to learn more about this report.

The hepatitis B (HepB3) immunization coverage in the U.S. was 92.0% in 2021, lower than other developed nations such as Australia (95%), Japan (95.6%), and the U.K. (92.6%).


High Costs Associated with Multivalent Vaccines to Limit Market Expansion

The costs of combination vaccines, such as pentavalent and hexavalent vaccines indicated for several diseases, are higher than single antigen vaccines owing to the complex manufacturing process of these vaccines. Such elements have led to a limited sustainable supply and adoption of combination vaccines across the U.S., further limiting market growth.

  • As per CDC estimates published in July 2023, the Vaxelis and a hexavalent vaccine cost around USD 146.6 compared to a single valent hepatitis vaccine of USD 25.6.

Thus, soaring costs of combination vaccines limit its adoption nationwide, further hampering the U.S. market growth.


By Type Analysis

By type, the market is segmented into single antigen and combination. The combination segment dominated the market in 2022 owing to extensive advantages over a single antigen vaccine, such as action against several diseases, including hepatitis B, high immunogenicity, improved effectiveness, and lower pain & discomfort.

  • According to an article published by MDPI in March 2023, the hexavalent vaccines, compared to conventional hepatitis B vaccines, have benefits, including lowering the risk for infection, reducing the number of clinical visits, better handling, and fewer administration errors.

By Distribution Channel Analysis

Based on distribution channel, the market is segmented into government suppliers, hospitals & retail pharmacies, and others.

The hospitals & retail pharmacies segment held the highest market share in 2022 due to the high volume of first vaccination doses administered among newborn infants in the U.S. hospitals. Moreover, the rising supply of these vaccines from hospitals for public immunization programs across the country is expected to surge the vaccination uptake amongst the population, further propelling market growth.

  • According to data published by UNICEF in 2022, about 93.0% of children till 18 months of age received hepatitis b 3 dose vaccination across U.S. hospitals in 2022.


Rising Collaborations Among Key Players for New Product Development to Strengthen Their Market Share

The market is primarily consolidated by key manufacturers, such as Sanofi, GSK plc, and others. The prominent players are focusing on facilitating investments in production and R&D centers across the country, to boost vaccine development owing to high demand from government agencies for public immunization programs. These factors are expected to drive the U.S. hepatitis B vaccine market share.  

  • In July 2023, GSK plc announced the expansion of its state-of-the-art vaccine facility in Singapore with a USD 343.0 million investment to produce drug substances for Hepatitis B vaccines.

Similarly, other emerging players in the market, including Dynavax Technologies Corporation and VBI Vaccines, Inc., are continuously engaged in strategic collaborations with other industry players to develop advanced vaccines for preventing hepatitis B infection. Such initiatives by new market players are anticipated to drive market growth.

  • In July 2023, Biopharmaceutical Company VBI Vaccines Inc., announced the expansion of its hepatitis B virus (HBV) partnership with Brii Biosciences to work on preventing and treating the disease.



  • February 2023 - The U.S.-based company, Dynavax Technologies Corporation, announced that the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) had granted marketing authorization for its U.S. FDA-approved HEPLISAV B vaccine in the U.K. The authorization will expand the geographical presence of the vaccine in the Europe region.

  • June 2022 - VBI Vaccines Inc. announced the new long-term follow-up clinical data for its 3-antigen adult hepatitis B vaccine presented at the International Liver Congress (LLC) and European Association for the Study of the Liver (EASL) 2022.

  • May 2022 - GlaxoSmithKline plc announced the acquisition of Affinivax Inc., a biopharmaceutical company involved in developing a novel class of vaccines, including potent adjuvants. This acquisition strengthens the company’s R&D pipeline and access to potential new technology.


An Infographic Representation of U.S. Hepatitis B Vaccine Market

To get information on various segments, share your queries with us

The market research report provides a detailed market analysis and focuses on crucial aspects such as leading players, product types, and major indications of the product. Additionally, it offers insights into market trends and key industry developments such as mergers, partnerships, & acquisitions, and the impact of COVID-19 on the market. In addition to the factors mentioned above, the report includes the factors that have contributed to the market's growth in recent years with a regional analysis of different segments.

Report Scope and Segmentation



Study Period


Base Year


Estimated Year 


Forecast Period


Historical Period


Growth Rate

CAGR of 4.5% from 2023 to 2030


Value (USD Billion)


By Type

  • Single Antigen

  • Combination

By Distribution Channel

  • Hospitals & Retail Pharmacies

  • Government Suppliers

  • Others

Frequently Asked Questions

Fortune Business Insights says that the U.S. market size was USD 2.49 billion in 2022.

Registering a CAGR of 4.5%, the market will exhibit steady growth during the forecast period (2023-2030).

The combination segment led this market in 2022.

GSK plc, Sanofi, and Merck & Co., Inc. are the major players in the U.S. market.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts

Speak to an Expert
  • 2019-2030
  • 2022
  • 2019-2021
  • 60

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Client Testimonials

“We are quite happy with the methodology you outlined. We really appreciate the time your team has spent on this project, and the efforts of your team to answer our questions.”

- One of the largest & renowned medical research centers based in the U.S. on a report on the U.S. NIPT Market.

“Thanks a million. The report looks great!”

- Feedback from a consultant on a report on the U.S. Beef Market.

“Thanks for the excellent report and the insights regarding the lactose market.”

- Brazil based company specializing in production of protein ingredients.

“I liked the report; would it be possible to send me the PPT version as I want to use a few slides in an internal presentation that I am preparing.”

- Global Digital Services Agency on a report on the Global Luxury Goods Market.

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.